ELDN · Eledon Pharmaceuticals, Inc.
$3.20
-0.12 (-3.61%)
At close · Aug 28
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that substantial doubt exists about our ability to continue as a going concern. Although management intends to obtain additional financing through the sources described above, these plans are subject to market conditions and other factors outside our control. Accordingly, management has concluded that its plans do not alleviate the substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$269.79M
Shares
81.26M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2016
Net Income
-$45.62M
-26.1%
FY2025
Diluted EPS
-$0.52
+21.2%
FY2025
Operating Cash Flow
-$62.34M
-31.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | $0 | $0 | — | — | — | |
| $67.89M | $66.27M | $51.96M | $30.31M | $27.08M | $23.74M | $6.13M | $8.13M | $6.82M | $2.02M | $3.19M | $32.64M | $14.58M | $12.2M | $7.37M | |
| $16.72M | $16.98M | $18.61M | $12.69M | $12.7M | $13.13M | $10.05M | $6.06M | $7.24M | $11.1M | $1.94M | $12.62M | $8.89M | $3.55M | $2.28M | |
| — | — | — | — | — | — | $5000 | $9000 | $11K | $22K | $35K | — | — | — | — | |
| — | — | — | — | — | $2.3M | $2.28M | — | — | — | — | — | — | — | — | |
| $84.6M | $83.25M | $70.58M | $43M | $88.43M | $36.87M | $18.47M | $16.05M | $14.06M | $13.12M | $5.13M | $45.26M | $23.46M | $15.75M | $9.65M | |
| — | — | — | -$43M | -$88.43M | -$36.87M | -$18.47M | -$16.05M | -$14.06M | -$13.12M | -$5.13M | -$45.26M | -$23.46M | -$15.75M | -$9.65M | |
| — | — | — | — | — | — | -$18.46M | -$16.04M | -$14.05M | -$13.1M | -$5.09M | — | — | — | — | |
| $3.57M | $4.22M | $3.92M | $2.67M | $462K | $7000 | $79K | $40K | -$5000 | $5000 | -$527K | — | $166K | $24K | — | |
| — | -$45.58M | -$35.75M | -$116.54M | -$87.97M | -$36.86M | -$23.22M | -$16.01M | -$14.07M | -$13.12M | -$5.66M | — | — | — | — | |
| — | $35K | $431K | $0 | $0 | -$2.35M | -$404K | — | — | — | $0 | $0 | $0 | $0 | — | |
| -$98.56M | -$45.62M | -$36.18M | -$116.54M | -$87.97M | -$34.51M | -$22.81M | -$16.01M | -$14.07M | -$13.12M | -$5.66M | -$45.09M | -$23.3M | -$15.73M | -$9.65M | |
| -$93.14M | -$42.33M | -$31.99M | — | — | — | — | — | — | — | — | -$45.09M | -$23.3M | -$15.82M | -$9.68M | |
| -$98.63M | -$45.62M | -$36.18M | — | — | — | — | — | — | — | -$37.91M | -$45.14M | -$23.3M | -$15.73M | — | |
| USD/shares | -$0.91 | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.91 | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | — | — | — | — | — | — | — | — | — |
| shares | — | 81.84M | 48.54M | 24.62M | 14.29M | 14.82M | 1.45M | 655.53K | 500.3K | 259.87K | 21.26K | 1.25M | 359.4K | 23.11K | 17.3K |
| shares | — | 81.84M | 48.54M | 24.62M | 14.29M | 14.82M | 1.45M | 655.53K | 500.3K | 259.87K | 21.26K | 1.25M | 359.4K | 23.11K | 17.3K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.37×
EV/EBIT
—
Peer median 9.14×
P/E (TTM)
—
Peer median 11.54×
Peer medians compare against the 310 similar-size Biotechnology companies (of 508 listed).
Key facts
CIK
1404281
CUSIP
28617K101
13F (30d)
123 filings
122 filers
Visit website
Investor relations